Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
ApexOnco Front Page
Recent articles
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Mocertatug rezetecan is starting its first western pivotal trials.
The holiday period included Genmab’s discontinuation of acasunlimab.
A deal with Jacobio is worth $100m up front.
Nenocorilant features among the latest industry projects newly into phase 1.
Two new PD-(L)1 x VEGF projects have entered the clinic.
